Abstract
Introduction
Cardiogenic shock (CS) is a state characterized by acute cardiac failure leading to low cardiac output, hypotension, and end-organ hypoperfusion [1] . CS is mostly related to acute coronary syndrome (ACS) and its mortality remains high despite improvements in ACS revascularization therapies [2] . The pharmacologic treatment of CS may require the combination of vasopressor therapy to restore and maintain systemic blood pressure and/ or inotropic support to improve cardiac output. Hence, agents such as epinephrine and norepinephrine have been recommended owing to their cardiac and/or vascular benefits via alpha-and beta-adrenergic receptor stimulation [3, 4] .
However, the use of catecholamines in acute heart failure may be associated with higher short-and long-term mortality [5, 6] . Among catecholamines, retrospective analyses have linked the need for epinephrine to worse outcome in patients with myocardial infarction or treated with mechanical circulatory support [7, 8] . More recently, data from a prospective patient cohort [9] and two small randomized trials [10, 11] suggest that in cardiogenic shock, epinephrine might be associated with detrimental short-term outcome.
Accordingly, we performed a systematic review of all studies assessing cardiogenic shock treatment and shortterm mortality using individual patient data. Across multiple cohorts with varying prevalence of epinephrine use and mortality, we sought to evaluate the association between epinephrine use and short-term outcome in CS. We hypothesized that epinephrine use was associated with a higher mortality compared to other inotrope(s) and/or vasopressor(s) regimen in cardiogenic shock patients.
Methods

Search strategy and selection of articles
We performed a systematic search of MEDLINE, Cochrane, and Web of Science databases using the following detailed search terms: Adrenaline, Epinephrine, Catecholamines, Vasopressors, Inotropes, and Cardiogenic shock, excluding articles in a language other than English, published prior to January 1, 1995, and case reports. The prespecified keyword combination used to run the literature search was "Adrenaline" [ (Fig. 1 ). Studies were included if they met the following prespecified inclusion criteria: (1) patients in cardiogenic shock treated with inotropes and/or vasopressors excluding postoperative CS and (2) at least 15% of patients of each study should have been treated with epinephrine used alone or in association with other inotropes/vasopressors. All findings are reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis of Individual Participant Data (PRISMA-IPD) [12] . The quality of the included studies was assessed using the Newcastle-Ottawa scale [13] .
Data extraction
Two investigators (V.L. and T.C.) performed the initial screening of titles and abstracts. Full-text reports of potentially relevant articles were obtained and assessed by both investigators using a prespecified protocol (PROSPERO Registration Number CRD42017082370). Two investigators (E.G. and A.M.) adjudicated all disagreements. Corresponding author(s) of each eligible cohort were contacted with a request for anonymized individual data sets and prespecified covariates: age, sex, medical history, systolic and diastolic blood pressure (SBP/DBP), heart rate (HR), left ventricular ejection fraction (LVEF), Acute Physiology and Chronic Health Evaluation II (APACHE II), Sepsis-related Organ Failure Assessment (SOFA), cause of CS, mechanical support [defined as extracorporeal life support (ECLS) or Impella; and ECLS defined as extracorporeal membrane oxygenation (ECMO) or left ventricular assist device (LVAD)], lactate, estimated glomerular filtration rate (eGFR), BNP or NT-proBNP, and troponin. All studies were conducted in accordance with the Declaration of Helsinki with approval from the regional ethics committee or institutional review board.
Analysis population and primary outcome
The analysis population comprised patients with all causes of CS treated with epinephrine versus others catecholamines. Patients who presented post cardiac arrest were included in the analysis. The prespecified primary outcome was short-term mortality whether at 28 or 30 days, during ICU or hospital stay. The number of patients available for analysis is shown in Table 1 .
Statistical analysis
Data were expressed as median and quartiles for continuous variables and numbers and percentages for nominal variables. The main outcome measure was short-term mortality. The analysis of the combined data was conducted using Metafor Package and the R statistical software [14] .
One purpose of the present study was to conduct metaregression to assess the relation between mortality rate and the rate of epinephrine use. A linear mixed-effect model was used to assess association. Random-effects models were used for the meta-analysis of the effect of epinephrine on mortality. Results were summarized as odds ratio (OR) with 95% confidence interval (95% CI). Adjustment for main prognostic variables (age, gender, ischemic heart disease, eGFR, and LVEF at admission) was also considered. Moreover, given the observational nature of the data, treatment allocation was not randomly allocated in the study population. The risk of allocation bias due to the presence of confounders was handled using propensity score (PS) matching [15] . Using PS matching, we could estimate the causal effect of the exposure on the outcome more precisely assuming a set of identifiability and causal assumptions. The PS was estimated from the observed data using a logistic regression model including a set of variables selected among available baseline variables (age, gender, LVEF, ACS as cause of CS, eGFR, HR, and low blood pressure). Each patient treated with epinephrine was matched to one untreated control with similar PS using the nearest-neighbor approach, with no replacement and a caliper size of 0.15. In this approach, each treated subject was matched to the nearest untreated subject within a specified maximum difference in the PS between two matched subjects (so-called caliper). Covariate balance between the two groups before and after PS matching was assessed using the mean standardized differences (MSD). An absolute MSD less than 10% was considered to support the assumption of balance between the groups. Subgroups analyses were also considered. In particular, the population was dichotomized according to median value of LVEF, natriuretic peptides, and troponin levels. To take into account intercenter variability regarding the measurement of those three continuous parameters, median values used for the dichotomization were assessed within each center. All statistical analyses were performed using R statistical software with the statistical package MatchIt for the matching process (R Foundation for Statistical Computing, Vienna, Austria; http://www. jstat soft.org/v42/i08/).
Results
Systematic review
The initial search found 228 studies (Fig. 1) , of which 67 were eligible for full text review and 39 studies were included. Authors consented to provide individual participant data from 14 published cohorts and 2 unpublished data sets.
Characteristics of the 16 included cohorts are described in Table 1 . Of note, 12 were observational cohorts [5, 9, [16] [17] [18] [19] [20] [21] [22] [23] and 4 were randomized controlled trials, but only one compared epinephrine and norepinephrine on outcome [11, [24] [25] [26] . The quality of the nonrandomized included studies was assessed using the NewcastleOttawa scale (Supplemental Table 1 ). The main characteristics of the 25 non-included cohorts are depicted in Supplemental Table 2 .
Study population
Individual patient-level data were obtained for a total population of 2583 patients with CS (Table 2 ) of which 462 (18%) occurred after resuscitation of cardiac arrest. In our studied population of CS patients, the incidence of epinephrine use was 37%, ranging from 17% to 76% across all cohorts, and epinephrine was the third most used catecholamine after norepinephrine (54%) and dobutamine (47%) (Supplemental Table 3 ). Short-term mortality rate was 49%, ranging from 21% to 69%. Figure 2 shows a correlation between the percentage of epinephrine use and short-term death by cohort.
Epinephrine use and risk of short-term death
Across all cohorts (n = 16), risk of short-term death was significantly higher in epinephrine-treated patients (OR [CI] = 3.3 [2.8-3.9]) compared to patients treated with other drug regimens for CS (Fig. 3) . Of note, among the 16 cohorts, the majority had positive risk of death associated with the use of epinephrine whether statistically significant (n = 6) or as a trend (n = 7). Risk of short-term death with the use of epinephrine was also adjusted for age, gender, ischemic heart disease, eGFR and LVEF at admission in a subset of 1227 patients. The adjusted mortality risk remained striking in epinephrine-treated patients (adjusted OR = 4.7 [3.4-6.4]) (Fig. 4) .
Furthermore, after propensity score matching, two sets of 338 matched patients balanced for all considered characteristics were identified (Supplemental Table 4 ) and epinephrine use was associated with a strong detrimental impact on short-term mortality (OR = 4.2 [3.0-6.0]).
Sensitivity analysis showed persistent detrimental association between epinephrine use and short-term mortality. After exclusion of the largest cohort (AHEAD), the OR was 2.3 [1.9-2.8], with a robust estimation of the standard error (model with cluster effect). Figure 5 confirms that epinephrine use was significantly associated in all subgroups (including patients with acute coronary syndrome) except those who benefited from ECLS (189/671 (28%) without ECLS versus 58/124 (48%) with ECLS, p < 0.0001).
Discussion
Using a large cohort of collaborative meta-analysis of allcause cardiogenic shock patients, we demonstrated that epinephrine use is associated with a striking excess in mortality compared to other drug regimens. The association remains robust even after adjustment and propensity score matching and was consistent in the majority of the studied cohorts.
Our meta-analysis of individual data shows that epinephrine is frequently used in CS regardless of the mechanisms of CS, including those not related to cardiac arrest. Our study further shows that the use of epinephrine in CS was associated with several-fold increase in short-term risk of death in crude, adjusted, or propensity score analysis. This excess of mortality is present in all subgroups, except among those who benefited from ECLS. Mechanisms of lack of detrimental association between epinephrine use and ECLS in CS remains elusive. They might be (1) related to early withdrawal of epinephrine in patients under ECLS and/or (2) less "detrimental" effect of epinephrine in hearts with reduced myocardial wall stress, and enhanced coronary perfusion [27] . We observed a low rate of ECLS (7%) that might be Detailed data for every study are given in Supplemental Table 3 SBP systolic blood pressure, MBP mean blood pressure, DBP diastolic blood pressure, LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, PCI primary coronary intervention, CABG coronary artery bypass graft, IABP intra-aortic balloon pump, ICU intensive care unit Fig. 2 Association between short-term mortality and the proportion of patients receiving epinephrine. Each circle represents one study. The radius of the circle is proportional to the cohort size explained by the recent increase in interest and use of mechanical support in cardiogenic shock management. The mechanism of possible epinephrine toxicity remains unclear. Detrimental effects of epinephrine might be related to worsening of cardiac condition, despite hemodynamic benefits [2, 9, 28] . Epinephrine increases oxygen consumption and alters calcium homeostasis more than other catecholamine [29] . Hence, in CS where cardiac condition is already severely altered, epinephrine might markedly aggravate cardiac metabolism leading to death. Epinephrine may similarly affect metabolism in other organs as recently shown in the OPTIMA CC and Cardshock studies [9, 11] . This may be due to epinephrine-induced alteration in microcirculation, specifically in the renal bed. These findings suggest that epinephrine's detrimental effect may be related to multiorgan toxicity [30] [31] [32] .
Our meta-analysis indicates that in CS, the risk/benefit ratio favors the administration of inotropes and/ or vasopressors other than epinephrine. Hence, the use of norepinephrine alone or combined with an inotrope, including dobutamine or levosimendan, may be recommended as recently suggested [3, 4, 9, 11, 33, 34] . Concerning cardiogenic shock following cardiac arrest, in patients already on continuous epinephrine, our data suggest that replacing epinephrine with other inotropes and/or vasopressors may be desirable.
Our study has several limitations. First, our analysis included mostly observational studies because of the paucity of randomized trials on the safety effect of epinephrine. In addition to a potential publication bias, we were also dependent on the cooperation of original investigators, not all of whom responded to our request for collaboration. However, our meta-analysis confirmed the result of the recently published OPTIMA CC [11] , the only randomized trial comparing epinephrine to norepinephrine. The results of the present meta-analysis are only exploratory. Prospective trials assessing the safety of epinephrine compared to other treatment regimen in cardiogenic shock are urgently needed. Second, we were confronted with many data available issues. This was expected as collaborating authors did not use the same data set in their studies, hindering the adjustment of our analysis for the full cohort. However, adjustment analysis, taking into account the severity of hemodynamic instability, and propensity score matching both confirmed the main result of the meta-analysis. Third, the impact of the quality of the studies on the risk of bias was not assessed in the present meta-analysis as only one of the 16 included cohorts originally aimed to assess the effect of epinephrine on mortality. Fourth, we were not able to collect data on dose or duration of epinephrine therapy or on its combination with other therapies (inotrope, vasopressor, or others). We were not able to assess whether there is a dose-dependent detrimental effect of epinephrine on outcome. However, our study shows that Fig. 5 Forest plot of the meta-analysis of short-term mortality, with subgroup analysis. ACS acute coronary syndrome, HR heart rate, BP blood pressure (low BP, MAP < 65 mmHg or SBP < 90 mmHg), EF ejection fraction, NP natriuretic peptide, Trop troponin, MR mortality rate. Low/high cutoff was defined as the median value within each cohort epinephrine was consistently associated with worse outcome in almost every study, regardless of illness severity and heterogeneity in CS management. More importantly, our analysis showed that mortality of each study was positively associated with the proportion of CS patients treated with epinephrine. Finally, the primary endpoint (short-term mortality) may appear restrictive and inadequate for the 462 patients resuscitated from cardiac arrest. It would have been interesting to associate neurological recovery. The cerebral performance categories scores (CPC scores) were not available in the database and should be evaluated in further studies.
Conclusion
Using a large collaborative meta-analysis, our study shows that epinephrine is associated with a threefold increase in risk of mortality in CS. This result highlights the need to perform controlled trials of different drug therapies in CS and supports the need to reconsider the use of epinephrine in future guidelines.
